Bulletin

Investor Alert

Sorrento Therapeutics Inc.

NAS: SRNE

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders

/marketstate/country/us

Sorrento Therapeutics Inc.

After Hours

--Quotes are delayed by 20 min

Feb 3, 2023, 7:58 p.m.

SRNE

/zigman2/quotes/205669265/composite

1.03

Change

+0.01 +0.98%

Volume

Volume 223,938

Quotes are delayed by 20 min

/zigman2/quotes/205669265/composite

Today's close

$ 1.02

Change

0.00 0.00%

Day low

Day high

$0.98

$1.06

52 week low

52 week high

$0.74

$3.60

Company Description

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

Valuation

Price to Sales Ratio

25.91

Price to Book Ratio

18.58

Enterprise Value to EBITDA

-1.68

Enterprise Value to Sales

9.81

Efficiency

Total Asset Turnover

0.08

Liquidity

Current Ratio

1.24

Quick Ratio

1.18

Cash Ratio

0.91

Profitability

Gross Margin

67.54

Operating Margin

-695.68

Pretax Margin

-874.28

Net Margin

-809.63

Return on Assets

-62.45

Return on Equity

-351.23

Return on Total Capital

-117.62

Capital Structure

Total Debt to Total Assets

30.74

Officers and Executives

Name	Age	Officer Since	Title
Dr. Henry H. Ji	57	2006	President, Chief Executive Officer & Director
Dr. Shawn Sahebi	-	-	Senior Vice President-Strategy & Analytics
Ms. Elizabeth Adkins Czerepak	65	2021	Independent Director
Dr. Robert D. Allen	-	-	Senior Vice President-Research & Development
Dr. Mike A. Royal	66	2014	Chief Medical Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions

Date Name Shares Transaction Value

12/21/2022	Henry H. Ji See Remarks; Director	300		1,650
12/15/2022	Henry H. Ji See Remarks; Director	1,500,000	Award at $0 per share.	0
12/02/2022	Henry H. Ji See Remarks; Director	200		1,100
09/07/2022	Henry H. Ji See Remarks; Director	88,888	Acquisition at $2.02 per share.	179,553
09/06/2022	Henry H. Ji See Remarks; Director	55,555	Acquisition at $1.96 per share.	108,887
09/02/2022	Henry H. Ji See Remarks; Director	2,500,000	Award at $0 per share.	0
08/26/2022	Henry H. Ji See Remarks; Director	33,333	Acquisition at $2.11 per share.	70,332
08/25/2022	Henry H. Ji See Remarks; Director	22,222	Acquisition at $2.06 per share.	45,777
06/14/2022	Henry H. Ji See Remarks; Director	10,000	Acquisition at $1.4 per share.	14,000
12/27/2021	Kim D. Janda Director	3,000	Disposition at $5.88 per share.	17,640
12/27/2021	Kim D. Janda Director	3,000	Derivative/Non-derivative trans. at $4 per share.	12,000

/news/latest/company/us/srne

MarketWatch News on SRNE

Biotech Stocks Are Up by Double Digits. It's Still a Bear Market.

7:48 a.m. July 25, 2022

- Barron's Online
Sorrento Therapeutics' Covistix rapid tests outperforms in detecting omicron variant in initial lab tests

9:42 a.m. Dec. 27, 2021

- Tomi Kilgore
Sorrento Therapeutics says initial testing showed its COVISTIX test demonstrated ability to detect omicron variant

9:25 a.m. Dec. 27, 2021

- Tomi Kilgore
Sorrento Therapeutics triples number of its rapid COVID-19 tests distributed in Mexico

9:23 a.m. Dec. 27, 2021

- Tomi Kilgore
Sorrento Therapeutics started at buy with $26 stock price target at B. Riley

7:46 a.m. Jan. 29, 2021

- Tomi Kilgore
Charting market rotation, S&P 500 presses record territory

12:40 p.m. Jan. 26, 2021

- Michael Ashbaugh
Charting market rotation, S&P 500 presses record territory

12:16 p.m. Jan. 26, 2021

- Michael Ashbaugh
These are the non-pharma winners and losers from the Pfizer vaccine results

5:28 p.m. Nov. 10, 2020

- Michael Brush
Sorrento stock falls after company fires CFO

4:57 p.m. Aug. 18, 2020

- Wallace Witkowski
‘Clueless’ investors just keep driving this ‘stupidly bullish’ stock market higher, CNBC’s Jim Cramer says

12:01 p.m. Aug. 5, 2020

- Shawn Langlois
Sorrento Therapeutics, A Small Biotech, Licenses Quick Covid-19 Spit Test

7:01 a.m. July 29, 2020

- Barron's Online
Sorrento Therapeutics stock is a buy on the 50% chance of a COVID-19 antidote, analyst says

6:28 a.m. May 27, 2020

- Tomi Kilgore
Dow closes up 500 points, tests 25,000 level, on recovery hopes and vaccine news

3:42 p.m. May 26, 2020

- Joy Wiltermuth
Sorrento Therapeutics started at buy with $24 stock price target at Dawson James Securities

6:30 a.m. May 26, 2020

- Tomi Kilgore
America’s New Pastime: Day Trading

8:40 a.m. May 23, 2020

- Barron's Online
Sorrento stock's intraday high of $10 was nearly 4 times Thursday's closing price

1:39 p.m. May 18, 2020

- Tomi Kilgore
Sorrento Therapeutics' stock gains 1.9%, but pares earlier surge of as much as 48%

1:38 p.m. May 18, 2020

- Tomi Kilgore
Here’s what it will take for the stock market to hit a new record within 2 months

1:05 p.m. May 18, 2020

- Nigam Arora
Stocks Rise Because There Is ‘No Limit’ to What Fed Can Do

6:48 a.m. May 18, 2020

- Barron's Online
Sorrento Therapeutics' stock soars 44% premarket, after rocketing 158% on Friday

6:30 a.m. May 18, 2020

- Tomi Kilgore
Loading more headlines...

/news/nonmarketwatch/company/us/srne

Other News on SRNE

Shares of newly public biotech Scilex climb 4% following SPAC merger (update)

4:20 p.m. Nov. 11, 2022

- Seeking Alpha
Sorrento: Limited Potential, High Management Compensation, Complicated Lawsuits

2:29 p.m. Nov. 9, 2022

- Seeking Alpha
ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates

8:05 a.m. Nov. 9, 2022

- Zacks.com
Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates

5:15 p.m. Nov. 8, 2022

- Zacks.com
10-Q: SORRENTO THERAPEUTICS, INC.

4:34 p.m. Nov. 8, 2022

- Edgar Online - (EDG = 10Q, 10K)
Sorrento Therapeutics: Down The Rabbit Hole

11:34 p.m. Nov. 7, 2022

- Seeking Alpha
Catalyst watch: CPI downtick, election ripples, Disney and Rivian earnings, Roblox conference call

12:30 p.m. Nov. 4, 2022

- Seeking Alpha
Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Misses Revenue Estimates

8:15 a.m. Oct. 27, 2022

- Zacks.com
Sorrento in credit agreement with B. Riley for $41.7M

2:36 p.m. Sept. 30, 2022

- Seeking Alpha
Morphic Holding, Inc. (MORF) Moves 7.3% Higher: Will This Strength Last?

9:15 a.m. Sept. 29, 2022

- Zacks.com
Sorrento Sofusa drug delivery system shows promise vs subcutaneous injection in trial

11:04 a.m. Sept. 15, 2022

- Seeking Alpha
Sorrento (SRNE) Gets FDA Fast Track Tag for Back Pain Product

11:45 a.m. Sept. 1, 2022

- Zacks.com
Why Sorrento Therapeutics Stock Is Marching Higher Today

11:01 a.m. Aug. 31, 2022

- Motley Fool
Hot Stocks: SRNE gains on FDA news, CHS rises on earnings, HPQ dips on Q3 estimates, and OSCR falls

7:16 a.m. Aug. 31, 2022

- Seeking Alpha
Sorrento stock rises 13% on FDA fast track status for low back pain therapy SP-103

3:40 a.m. Aug. 31, 2022

- Seeking Alpha
Sorrento (SRNE) Up on Positive Result From Lung Cancer Study

11:24 a.m. Aug. 24, 2022

- Zacks.com
2 Penny Stocks That Could Make You Filthy Rich

8:45 a.m. Aug. 24, 2022

- Motley Fool
Why Sorrento Therapeutics Stock Is Popping Today

2:08 p.m. Aug. 23, 2022

- Motley Fool
Sorrento achieves positive results in pivotal trial for abivertinib in NSCLC

9:45 a.m. Aug. 23, 2022

- Seeking Alpha
Sorrento Therapeutics: COVISTIX Sales Are Lagging Behind

1:21 a.m. Aug. 20, 2022

- Seeking Alpha
Loading more headlines...

At a Glance

Sorrento Therapeutics, Inc.

4955 Directors Place

San Diego, California 92121

Phone

1 8582034100

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

View SEC Filings

Revenue

$52.90M

Net Income

$-428.33M

Employees

799.00

Annual Report for SRNE

/news/pressrelease/company/us/srne

Press Releases on SRNE

Sorrento Releases Positive Results from a Phase 1b Study in China in COVID-19 Patients and is Ready for Pivotal Phase 3 trials with OVYDSO(TM) (STI-1558), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting

9:00 a.m. Jan. 9, 2023

- GlobeNewswire
Sorrento Therapeutics has Received FDA Clearance to Initiate Clinical Trials with a Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 Virus

9:00 a.m. Dec. 6, 2022

- GlobeNewswire
Sorrento Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology (ESMO)

3:01 p.m. Dec. 5, 2022

- GlobeNewswire
Sorrento Releases Positive Topline Results from the Phase I Study Completed in Australia and Preliminary Results from a Phase Ib Study in China with STI-1558, an Oral M(pro) Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting

2:06 p.m. Nov. 29, 2022

- GlobeNewswire
Sorrento to Host Webcast to Discuss Newly Presented Clinical Data Demonstrating Significant Improvements in Therapeutic Outcomes in 10 of 10 Patients with Poorly Controlled Rheumatoid Arthritis

3:03 p.m. Nov. 13, 2022

- GlobeNewswire
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), Debuts on Nasdaq Under Ticker "SCLX"

2:46 p.m. Nov. 10, 2022

- GlobeNewswire
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), and Vickers Vantage Corp. I Announce the Closing of their Previously Announced Business Combination

2:15 p.m. Nov. 10, 2022

- GlobeNewswire
Scilex Holding Company ("Scilex"), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, "Sorrento"), and Vickers Vantage Corp. I Announce Effectiveness of Registration Statement on Form S-4, Date of Vickers Vantage Extraordinary General Meeting to Approve Proposed Business Combination

8:01 a.m. Oct. 31, 2022

- GlobeNewswire
Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study for Sorrento Therapeutics, Inc. on Lymphatic Etanercept Delivery in Rheumatoid Arthritis Patients With Results To Be Presented at the 2022 American College of Rheumatology Conference

6:01 a.m. Oct. 26, 2022

- ACCESSWIRE
Why is Sorrento Therapeutics (SRNE Stock) Rising Today?

10:34 a.m. Oct. 21, 2022

- PressReach.com
Sorrento Successfully Completes Phase 1 Study and Is Proceeding to Implement Global Registrational Trials with STI-1558, an Oral Mpro Inhibitor as a Standalone Oral Treatment and Prevention of COVID-19 without the Need for a Ritonavir Booster

8:00 a.m. Oct. 17, 2022

- GlobeNewswire
Sorrento Announces Publication of Data in Cell Press Journal Med Describing Discovery and Preclinical Efficacy of a Broadly-Acting SARS-CoV-2 Neutralizing Antibody Administered IV (STI-9167) or IN (STI-9199)

1:57 p.m. Oct. 14, 2022

- GlobeNewswire
Sorrento Therapeutics to Participate in Key Opinion Leader Panel Discussion on "New Horizons for the Treatment of Non-small Cell Lung Cancer"

8:00 a.m. Oct. 6, 2022

- GlobeNewswire
Why Did SRNE Stock Drop 23.4% in September?

1:18 p.m. Oct. 5, 2022

- PressReach.com
Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Pay Off of Remaining Balance of its Senior Secured Notes

8:00 a.m. Sept. 29, 2022

- GlobeNewswire
Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients

8:01 a.m. Sept. 26, 2022

- GlobeNewswire
Sorrento Stock Price Down 5.3%

10:30 a.m. Sept. 22, 2022

- PressReach.com
Sorrento Announces the Publication in the Nature Journal Scientific Reports the Details of the Discovery of SARS-CoV-2 Neutralizing Antibodies from the G-MAB Library

2:34 p.m. Sept. 15, 2022

- GlobeNewswire
Sorrento Reports Positive Trial Results Utilizing Sofusa Lymphatic Delivery of Etanercept, Achieving Significant Improvements in Rheumatoid Arthritis Disease Measures at 50% of the Standard Dose for Patients (7 of 7) with an Inadequate Response to Subcutaneous Injections

8:00 a.m. Sept. 15, 2022

- GlobeNewswire
Sorrento Therapeutics to Participate in Morgan Stanley 20th Annual Global Healthcare Conference September 12-14

8:00 a.m. Sept. 8, 2022

- GlobeNewswire
Loading more headlines...

MarketWatch.com

Follow MarketWatch
RSS
Podcasts

Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

Sorrento Therapeutics Inc.

Company Description

Valuation

Efficiency

Liquidity

Profitability

Capital Structure

Officers and Executives

Insider Actions

MarketWatch News on SRNE

Other News on SRNE

At a Glance

Press Releases on SRNE

Latest News

dow

nasdaq

s&p 500

Kiosk